Welcome To

InflaRx - controlling inflammation

Read more...

InflaRx develops new first-in-class therapeutics

targeting acute and chronic inflammation. Our primary focus is on the development of monoclonal antibodies that target activation products of the complement system for application in life-threatening inflammatory diseases. We are a team of internationally recognized researchers and clinicians who have dedicated our careers to translating discoveries and expertise into new therapeutic concepts for clinical application.

InflaRx Business

InflaRx initiates exploratory phase II trail with IFX-1

C5a is a key player in many acute and chronic inflammatory processes. Thus, C5a is a highly attractive pharmacological target. However, a special Technology is required to effectively control this target. 

read more ...

Lorem ipsum dolor

InflaRx develops highly specific monoclonal antibodies targeting activation products of the complement system. InflaRx has made breakthrough discoveries in the area of anti-C5a antibody generation, resulting in a new class of highly selective antibodies with exceptional blocking activities.

read more ...

Clinical Programs

InflaRx focuses on diseases with high unmet medical need. IFX-1, the company's first-in-class anti-human C5a monoclonal antibody is currently being developed in two disclosed, and other non-disclosed, chronic inflammatory diseases within the orphan drug and autoimmmune disease space. 

read more ...

about IFX-1

The latest information on InflaRx share price with interactive charts, comparative analysis, historic figures and latest trade price is available here.

read more ...

Stock Price

IFX-1

Our lead drug candidate, IFX-1, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical phase II development. read more ...

IFX-2

IFX-2 is a follow-on project to IFX-1, in preclinical development. IFX-2 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered pharmacokinetic properties. read more ...

InflaRx News